Mereo BioPharma Stock Price - MREO

1.26
-0.01 (-0.79%)
Upgrade to Real-Time
Regular Market
1.26
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Mereo BioPharma Group PLC MREO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.01 -0.79% 1.26 1.24 1.26 1.24 1.27 10:10:26
Bid Price Ask Price Spread Spread % News
1.25 1.27 0.02 1.57% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10 9,794 $ 1.24 $ 12,170 77,518 0.69 - 5.00
Last Trade Time Type Quantity Stock Price Currency
10:10:26 150 $ 1.26 USD

Mereo BioPharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 31.38M 24.90M 24.90M $ - $ - -2.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Mereo BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MREO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.201.301.201.2558,2720.065.0%
1 Month1.361.471.101.2665,230-0.10-7.35%
3 Months1.891.940.691.2770,883-0.63-33.33%
6 Months2.383.740.692.17176,990-1.12-47.06%
1 Year4.165.000.692.2497,866-2.90-69.71%
3 Years6.556.56590.692.3391,370-5.29-80.76%
5 Years6.556.56590.692.3391,370-5.29-80.76%

Mereo BioPharma Description

Mereo BioPharma Group PLC is a multi-asset biopharmaceutical company. It is focused on the acquisition, development, and commercialization of innovative therapeutics to improve outcomes for patients with rare and specialty diseases. The company portfolio consists of clinical-stage product candidates that include BPS-804 (setrusumab), AZD-9668 (alvelestat), BGS-649 (leflutrozole), OMP-313M32 (etigilimab), OMP-305B83 (navicixizumab) and BCT-197 (acumapimod).


Your Recent History
NASDAQ
MREO
Mereo BioP..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.